Adis Journals
Browse

Randomized, Open-label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged ≥65

Download (1.6 MB)
media
posted on 2024-06-12, 16:23 authored by AdisRapid Journals on behalf of:, Robert Buynak, Kevin Cannon, David DeAtkine, John Kirby, Lisa Usdan, Amit Bhavsar, Catherine Gérard, Anastasia Kuznetsova, Amulya Jayadev, Hiwot Amare, Sofia Valenciano, Nadia Meyer

  

Article full text

 The article associated with this page has been accepted for online publication and is in the final stages of production. The link to the full text will be made available on this page in the next few days.

 The above graphical abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer-reviewed publication” opposite). 

History

Usage metrics

    Infectious Diseases and Therapy

    Categories

    Keywords

    high-dosequadrivalent influenza vaccine (FLU-QIV-HD)immunogenicityolder adultsRandomized Controlled Trial BackgroundHealthcare personnel influenza immunization ratesreactogenicityRespiratory Syncytial Virus (RSV)RSV prefusion protein F3 older adult (RSVPreF3 OA) vaccinesafetygraphical abstract

    Licence

    CC BY-NC 4.0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC